Gastrointestinal infections in immunocompromised hosts

Area of Science:

• Immunology
• Infectious Diseases
• Transplantation Medicine

Background:

• The global population of immunocompromised individuals is increasing due to factors like HIV infection, organ transplantation, stem cell transplantation, and leukemia treatments.
• These patients face a heightened risk of gastrointestinal infections, leading to significant morbidity and mortality.
• Understanding the specific state of immunosuppression is vital for managing infections in these individuals.

Purpose of the Study:

• To review emerging pathogens, diagnostic tools, guidelines, and therapies for gastrointestinal infections in immunocompromised patients, focusing on HIV and solid organ transplantation.
• To highlight recent advancements and challenges in managing these infections.
• To emphasize the importance of evaluating infection status before altering immunosuppressive medications.

Main Methods:

• Literature review of studies published within the last 12 months.
• Focus on research related to HIV, solid organ transplantation, and gastrointestinal infections.
• Synthesis of findings on new pathogens, diagnostics, and therapeutic strategies.

Main Results:

• Echinocandins offer new treatment options for Candida esophagitis.
• Mycobacterium avium complex therapy may be discontinued upon immune reconstitution in HIV patients.
• Emerging antimicrobial-resistant bacteria and viruses pose a significant threat, particularly in resource-limited settings.
• Community viruses like adenovirus can cause severe illness in immunocompromised hosts.
• A strong correlation exists between immunosuppressive medications, diarrhea, and transplant rejection, necessitating infection evaluation.

Conclusions:

• The rising number of immunocompromised hosts worldwide leads to increased exposure to novel gastrointestinal pathogens.
• Advances in diagnostics and antimicrobial therapies are improving outcomes for those with healthcare access.
• The growing challenge of multidrug-resistant organisms requires innovative management strategies.
• Restoring immune function, through antiretroviral therapy or reduced immunosuppression, is paramount for successful infection control.